Publication date: September 2026 Source: ESMO Gastrointestinal Oncology, Volume 13, Part B Author(s): A. Gordon, E. Cartwright, A. Tran, R. Crux, F. Turkes, E. Smyth, A. Smith, I. Manalang, I. Rana, D. Kohoutova, E. Johnston, A. Dunlop, M.S. Ul-Islam, S. Falk, A. Sita-Lumsden, S. Rao, N. Starling, I. Chau, D. Cunningham
DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial. // ESMO Gastrointestinal Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2949819826001068?dgcid=rss_sd_all
DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial. ESMO Gastrointestinal Oncology. https://www.sciencedirect.com/science/article/pii/S2949819826001068?dgcid=rss_sd_all
“DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial.” ESMO Gastrointestinal Oncology.
@article{article44802,
title = {DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial},
journal = {ESMO Gastrointestinal Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2949819826001068?dgcid=rss_sd_all}
}